Gimeracil/oteracil/tegafur - Taiho Pharmaceutical
Alternative Names: BMS-247616; CDHP/potassium-oxonate/tegafur; CIDU/potassium-oxonate/tegafur; Oteracil/tegafur/gimeracil; Potassium-oxonate/tegafur/CDHP; Potassium-oxonate/tegafur/CIDU; S-1; Tegafur/CDHP/potassium-oxonate; Tegafur/CIDU/potassium-oxonate; Tegafur/gimeracil/oteracil; Tegafur/potassium-oxonate/CDHP; Tegafur/potassium-oxonate/CIDU; Teysuno; TS-1; TS-1 combination capsules T20/T25; TS-1 combination granules T20/T25; TS-1 combination OD tablets T20/T25; TS-ONELatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Taiho Pharmaceutical
- Developer Helsinki University Central Hospital; Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
- Class Antineoplastics; Carboxylic acids; Furans; Halogenated hydrocarbons; Pyridines; Pyrimidinones; Small molecules; Triazines
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer
- Phase III Cervical cancer; Liver cancer; Oesophageal cancer; Squamous cell cancer; Uterine cancer
- Phase II Gastrointestinal cancer; Renal cancer
- No development reported Prostate cancer